Lilly Preps Abemaciclib To Take On Ibrance; Differentiation Still A Question

 
• By Jessica Merrill

The CDK4/6 inhibitor showed progression-free survival in patients with breast cancer in an interim analysis, and Lilly plans to begin global regulatory submissions for the drug in the second quarter.

Breast Cancer Awareness: Microscopic image (photomicrograph) of core biopsy for infiltrating (invasive) ductal carcinoma, detected by screening mammogram. H & E stain.

More from Anticancer

More from Therapy Areas